Top

Archives of Gynecology and Obstetrics

Published in:

01-10-2011 | Gynecologic Oncology

Inhibin-betaA and -betaB subunits in normal and malignant glandular epithelium of uterine cervix and HeLa cervical cancer cell line

Authors: Alexander Burges, Naim Shabani, Ansgar Brüning, Ioannis Mylonas

Published in: Archives of Gynecology and Obstetrics | Issue 4/2011

Abstract

Introduction

Inhibins, dimeric peptide hormones composed of an alpha-subunit and one of two possible beta-subunits (betaA or betaB), exhibit substantial roles in human reproduction and in endocrine-responsive tumors. However, it is still unclear if normal and cancerous cervical glandular epithelial cells as well as cervical cancer cell lines of glandular origin express the inhibin-betaA and -betaB subunits.

Materials and methods

Normal cervical tissue samples and a total of 10 specimens of well-differentiated adenocarcinomas of the human cervix were analyzed for inhibin-betaA and -betaB subunit expression by immunohistochemical analysis. Additionally, the cervical carcinoma cell line HeLa was analyzed by immunofluorescence and RT-PCR analysis for the expression of inhibin subunits.

Results

Immunolabeling of normal and malignant glandular epithelium of human cervical tissue revealed a positive staining reaction for the inhibin-betaA and -betaB subunits. Additionally, the cancer cell line HeLa synthesized both inhibin subunits. When compared to the normal cervical glandular epithelium, the expression of the inhibin beta subunits became significantly reduced in cervical adenocarcinoma tissues.

Discussion

In conclusion, we demonstrated a strong, though differential expression pattern of inhibin-betaA and -betaB subunits in normal and malignant glandular epithelial cells of the human uterine cervix. Although the physiological role of inhibins is still quite unclear in cervical tissue, the expression of inhibin-beta-subunits might play an important role in cervical cancer carcinogenesis, since they are significantly down-regulated during pathogenesis in cervical adenocarcinomas.

Franco EL, Schlecht NF, Saslow D (2003) The epidemiology of cervical cancer. Cancer J 9:348–359PubMedCrossRef

Waggoner SE (2003) Cervical cancer. Lancet 361:2217–2225. doi:10.1016/S0140-6736(03)13778-6 PubMedCrossRef

Gien LT, Beauchemin MC, Thomas G (2010) Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116:140–146. doi:10.1016/j.ygyno.2009.09.040 PubMedCrossRef

Wang X, Liu R, Ma B, Yang K, Tian J, Jiang L, Bai ZG, Hao XY, Wang J, Li J, Sun SL, Yin H (2010) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 7:CD007563. doi:10.1002/14651858.CD007563.pub2 PubMed

Wang N, Guan QL, Wang K, Zhou X, Gao C, Yang HT, Ni TG (2010) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet. doi:10.1007/s00404-010-1385-5 6

Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550–560. doi:10.1038/nrc2886 PubMedCrossRef

Barthell E, Woelber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E (2009) Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Arch Gynecol Obstet 279:803–807. doi:10.1007/s00404-008-0806-1 PubMedCrossRef

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527. doi:10.1056/NEJMoa0216413 PubMedCrossRef

zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384:260–265. doi:10.1016/j.virol.2008.11.046 PubMedCrossRef

10.

Han CP, Kok LF, Lee MY, Wu TS, Ruan A, Cheng YW, Wang PH, Koo CL, Tyan YS (2010) Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. Arch Gynecol Obstet 281:317–323. doi:10.1007/s00404-009-1115-z PubMedCrossRef

11.

Yao CC, Kok LF, Lee MY, Wang PH, Wu TS, Tyan YS, Cheng YW, Kung MF, Han CP (2009) Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet 280:405–413. doi:10.1007/s00404-008-0859-1 PubMedCrossRef

12.

Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S (2004) Activins and inhibins and their signaling. Ann N Y Acad Sci 1038:142–147PubMedCrossRef

13.

Xia Y, Schneyer AL (2009) The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202:1–12. doi:10.1677/JOE-08-0549 PubMedCrossRef

14.

Bergauer F, Bruning A, Shabani N, Blankenstein T, Juckstock J, Dian D, Mylonas I (2009) Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol 40:353–359. doi:10.1007/s10735-009-9246-x PubMedCrossRef

15.

Kimmich T, Bruning A, Kaufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I (2010) Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet 282:185–191. doi:10.1007/s00404-009-1310-y PubMedCrossRef

16.

Kaufl SD, Kuhn C, Kunze S, Shabani N, Bruning A, Friese K, Mylonas I (2010) Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer. Arch Gynecol Obstet doi:10.1007/s00404-010-1614-y

17.

Gingelmaier A, Bruning A, Kimmich T, Makovitzky J, Bergauer F, Schiessl B, Friese K, Mylonas I (2010) Inhibin/activin-betaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines. Arch Gynecol Obstet doi:10.1007/s00404-009-1340-5

18.

Weissenbacher T, Bruning A, Kimmich T, Makovitzky J, Gingelmaier A, Mylonas I (2010) Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem 58:751–757. doi:10.1369/jhc.2010.956185 PubMedCrossRef

19.

Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22:836–858PubMedCrossRef

20.

Mylonas I, Shabani N, Vogl J, Makovitzky J, Kunze S, Kuhn C, Schulze S, Friese K, Jeschke U (2007) Inhibin/activin subunits are immunohistochemically expressed in complete and partial hydatidiform moles. Anticancer Res 27:1995–2000PubMed

21.

Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Kunze S, Schulze S, Kainer F, Friese K (2006) Expression of inhibin/activin subunits alpha (-alpha), beta A (-beta (A)) and beta B (-beta (B)) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies. J Mol Histol 37:43–52PubMedCrossRef

22.

Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Schulze S, Kainer F, Friese K (2006) Expression of inhibin/activin subunits alpha (-alpha), betaA (-betaA), and betaB (-betaB) in placental tissue of normal, preeclamptic and HELLP pregnancies. Endocr Pathol 17:19–34PubMedCrossRef

23.

Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V, Friese K (2003) Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 268:142–150. doi:10.1007/s00404-003-0526-5 PubMedCrossRef

24.

Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B, Friese K (2005) Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. Arch Gynecol Obstet 272:59–66. doi:10.1007/s00404-004-0666-2 PubMedCrossRef

25.

Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K, Mylonas I (2007) Expression of the inhibin/activin subunits (-alpha, -betaA and -betaB) in normal and carcinogenic endometrial tissue: Possible immunohistochemical differentiation markers. Oncol Rep 17:97–104PubMed

26.

Mylonas I (2010) Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: Prognostic significance and clinical implications. Eur J Cancer 46:2485–2493. doi:10.1016/j.ejca.2010.06.001 PubMedCrossRef

27.

Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano P, Di Blasio AM, Genazzani AR, Vale W (1998) Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 83:1194–1200PubMedCrossRef

28.

Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS, Friese K (2004) Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122:461–471PubMedCrossRef

29.

Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45:1304–1314. doi:10.1016/j.ejca.2009.01.008 PubMedCrossRef

30.

Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K (2004) Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93:92–97PubMedCrossRef

31.

Otani T, Minami S, Kokawa K, Shikone T, Yamoto M, Nakano R (1998) Immunohistochemical localization of activin A in human endometrial tissues during the menstrual cycle and in early pregnancy. Obstet Gynecol 91:685–692PubMedCrossRef

32.

Gingelmaier A, Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K (2007) Expression of HPV, steroid receptors (ERalpha, ERbeta, PR-A and PR-B) and inhibin/activin subunits (alpha, betaA and betaB) in adenosquamous endometrial carcinoma. Anticancer Res 27:2011–2017PubMed

33.

Jückstock K, Brüning A, Blankenstein T, Kunze S, Shaban N, Bergauer F, Mylonas I (2010) Immunolabeling of the inhibin-betaA and -betaB subunit in normal and malignant human cervical tissue and cervical cancer cell line. Int J Gynecol Cancer 20:1177–1125

34.

Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K (2009) Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7:15. doi:10.1186/1478-811X-7-15 PubMed

35.

Blankenstein TJF, Jückstock JK, Shabani N, Kunze S, Brüning A, Bergauer F, Mylonas I (2010) Immunolabelling of the inhibin/activin-betaC subunit in normal and malignant human uterine cervical tissue and cervical cancer cell lines. Oncol Rep (in press)

36.

Bruning A, Makovitzky J, Gingelmaier A, Friese K, Mylonas I (2009) The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol 132:33–38. doi:10.1007/s00418-009-0595-z PubMedCrossRef

37.

Mylonas I (2010) Inhibin-betaA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation? Arch Gynecol Obstet doi:10.1007/s00404-010-1680-1

38.

Risbridger GP, Ball EM, Wang H, Mellor SL, Peehl DM (2004) Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol 225:73–76PubMedCrossRef

39.

Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, Shimizu K, Imamura T (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98:127–133PubMedCrossRef

40.

Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S (2008) Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 14:660–667PubMedCrossRef

41.

Farley J, Gray K, Nycum L, Prentice M, Birrer MJ, Jakowlew SB (2000) Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kip1). Gynecol Oncol 78:113–122PubMedCrossRef

42.

Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A (1992) Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313–319PubMedCrossRef

43.

Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A (1994) Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91:8817–8821PubMedCrossRef

44.

Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M (2003) Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112:575–587PubMed

45.

Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L, Rimokh R (2007) Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res 67:7223–7229PubMedCrossRef

46.

Ramachandran A, Marshall ES, Love DR, Baguley BC, Shelling AN (2009) Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett 285:157–165. doi:10.1016/j.canlet.2009.05.010 PubMedCrossRef

47.

Katik I, Mackenzie-Kludas C, Nicholls C, Jiang FX, Zhou S, Li H, Liu JP (2009) Activin inhibits telomerase activity in cancer. Biochem Biophys Res Commun 389:668–672. doi:10.1016/j.bbrc.2009.09.055 PubMedCrossRef

48.

Di Simone N, Crowley WF Jr, Wang QF, Sluss PM, Schneyer AL (1996) Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137:486–494PubMedCrossRef

49.

Di Simone N, Hall HA, Welt C, Schneyer AL (1998) Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells. Endocrinology 139:1147–1155PubMedCrossRef

50.

Di Simone N, Schneyer AL, Caliandro D, Castellani R, Caruso A (2002) Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol 192:187–195PubMedCrossRef

51.

Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF (2005) Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 3:50–61PubMed

Title: Inhibin-betaA and -betaB subunits in normal and malignant glandular epithelium of uterine cervix and HeLa cervical cancer cell line
Authors: Alexander Burges
Naim Shabani
Ansgar Brüning
Ioannis Mylonas
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-010-1734-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inhibin-betaA and -betaB subunits in normal and malignant glandular epithelium of uterine cervix and HeLa cervical cancer cell line

Abstract

Introduction

Materials and methods

Results

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 4/2011

Spontaneous uterine rupture at the 21st week of gestation caused by placenta percreta

Nifedipine for the treatment of preterm labor in twin and singleton pregnancies

Transumbilical single-incision laparoscopic hysterectomy with conventional laparoscopic instruments in patients with symptomatic leiomyoma and/or adenomyosis

Schizophrenia and Stein–Leventhal syndrome: comorbidity features

Robotic surgery in the management of cervical carcinoma

Endometrial expression of estrogen receptor β and its splice variants in patients with and without endometriosis